-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

4016 Management and Evolution after VTE Recurrence and/or Bleeding in Cancer Patients Receiving Anticoagulant Therapy for VTE: A Nationwide Cohort Study in France

Program: Oral and Poster Abstracts
Session: 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster III
Hematology Disease Topics & Pathways:
Research, Clinical Research, registries
Monday, December 11, 2023, 6:00 PM-8:00 PM

Isabelle Mahe, MD, PhD1*, Gaelle Gusto2*, Nadia Quignot3*, Artak Khachatryan4*, José Chaves5*, Audrey Moniot6*, Lucas André6*, Sylvain Van Roy6*, Ruth Mokgokong7* and Laurent Bertoletti, MD8*

1Internal Medicine department, Paris Cité University, Louis Mourier Hospital , APHP, Inserm UMR-S1140, Innovations Thérapeutiques en Hémostase, Paris, France, COLOMBES, France
2Certara France,, Paris, France
3Certara France, Paris, FRA
4Certara UK, Sheffield, United Kingdom
5Pfizer, Madrid, Spain
6Pfizer, Paris, France
7Pfizer, Tadworth, ENG, GBR
8CHU De St-Etienne, St-Etienne, FRA

BACKGROUND: Until recently, the standard of care for treatment of venous thromboembolism (VTE) in cancer patients was low molecular weight heparins (LMWH). Despite anticoagulation therapy (AC), patients remain at high risk of treatment failure (VTE recurrence and/or bleeding).

PURPOSE: To determine the characteristics, management and the course of treatment after experiencing a recurrent VTE and/or bleeding event in VTE cancer patients receiving LMWH.

METHODS: A nationwide retrospective cohort study of all adult patients (identified via the French national health data system: SNDS) with VTE and active cancer prescribed LMWH from 2013 to 2018.

RESULTS: Of 31,771 patients administered LMWH, 1,256 patients (mean age 64.1 years) experienced a recurrent VTE (median time to the first recurrent VTE event: 1.2 months) and 1,129 patients (mean age 67.5 years) experienced a bleeding event leading to hospitalization (median time to the first bleeding event: 1.5 months) during the first six months, and among them 46.7% and 40.9% patients experienced the event within the first month.

The proportion of patients with recurrent VTE and bleeding varied according to cancer sites (7.3%, 6.5% and 5.1% for recurrent VTE and 5.0%, 6.1% and 4.1% for bleeding, respectively in lung, colorectal and breast cancer) (Figure 1).

The management of patients with recurrent VTE consisted of a switch to another AC treatment in 370 patients, in whom 262 switched to an oral AC (179 to a DOAC and 83 to a VKA), the remaining continuing LMWH.

The management of patients with bleeding consisted of a switch to another AC treatment in 159 patients. Among the 159 switched patients, 94 switched to an oral AC (73 to a DOAC and 21 to a VKA), <10 stopped AC (Figure 2).

CONCLUSION: Our results indicate that recurrent VTE and bleeding events lead to a heterogenous switch of AC therapy. Further research is needed to optimize secondary AC management in VTE cancer patients.

This study was sponsored by Pfizer and Bristol Myers Squibb

Keywords : venous thromboembolism; cancer; anticoagulants; bleeding; low molecular weight heparin; treatment pattern

Disclosures: Mahe: LEO Pharma: Research Funding, Speakers Bureau; BMS PFIZER: Honoraria, Research Funding. Gusto: CERTARA: Current Employment. Quignot: CERTARA: Current Employment. Khachatryan: CERTARA: Current Employment. Chaves: PFIZER: Current Employment. Moniot: PFIZER: Current Employment. André: PFIZER: Current Employment. Van Roy: PFIZER: Current Employment. Mokgokong: PFIZER: Current Employment. Bertoletti: LEO pharma: Speakers Bureau; BMS Pfizer: Honoraria, Speakers Bureau; Aspen: Speakers Bureau; Bayer: Speakers Bureau.

*signifies non-member of ASH